Sansure Biotech Inc. (688289.SS)

CNY 22.2

(0.0%)

Market Cap (In CNY)

12.71 Billion

Revenue (In CNY)

1 Billion

Net Income (In CNY)

363.72 Million

Avg. Volume

3.26 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
16.08-25.58
PE
-
EPS
-
Beta Value
0.7
ISIN
CNE1000043J1
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Mr. Lizhong Dai
Employee Count
-
Website
https://www.sansure.com.cn
Ipo Date
2020-08-28
Details
Sansure Biotech Inc. develops and sells upstream nucleic acid extraction kits, real time PCR diagnostic and research kits, and fluorescence systems in China and internationally. The company offers novel coronavirus nucleic acid diagnostic kits; viral hepatitis and AIDS, blood screening, and extraction kits; cancer-related biomarkers; and kits for respiratory tract diseases, STDs, digestive tract diseases, prenatal and postnatal care, and genetic diseases, as well as instruments and other consumables. It serves hospitals and laboratories. The company was founded in 2008 and is based in Changsha, China.